Following a staggered development history set back by the "war on drugs", biotech firms have in recent years kick-started R&D into psychedelics, but despite a blooming clinical pipeline, the field has several challenges to overcome ranging from the risk-averse attitude of potential big pharma partners to identifying the right patients for treatment.
Psychedelics, also known as ‘classical hallucinogens’, are compounds which share a chemical structure similar to the neurotransmitter serotonin, and include...